EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Parnian Jamshidi iD, Yeganeh Farsi, Zahra Nariman iD, Mohammad Reza Hatamnejad, Benyamin Mohammadzadeh iD, Hossein Akbarialiabad, Mohammad Javad Nasiri iD, Leonardo A Sechi iD

International Journal of Molecular Sciences · 26.09.2023 · 24 (19) · 14562

DOI: 10.3390/ijms241914562 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.09.2023. Verfasst von Parnian Jamshidi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Irritable bowel syndrome (IBS) poses a significant challenge due to its poorly understood pathogenesis, substantial morbidity, and often inadequate treatment outcomes. The role of fecal microbiota transplantation (FMT) in managing IBS symptoms remains inconclusive. This systematic review and meta-analysis aimed to ascertain the effectiveness of FMT in relieving symptoms in IBS patients. A thorough search was executed on PubMed/Medline and Embase databases until 14 June 2023, including all studies on FMT use in IBS patients. We examined the efficiency of FMT in reducing patients’ symptoms overall and in particular subgroups, classified by placebo preparation, FMT preparation, frequency, and route of administration. Among 1015 identified studies, seven met the inclusion criteria for the meta-analysis. The overall symptomatology of FMT-treated IBS patients did not significantly differ from the control group (Odds Ratio (OR) = 0.99, 95% Confidence Interval (CI) 0.39–2.5). Multiple doses of FMT compared with non-FMT placebo, or single-donor FMT therapy compared with autologous FMT placebo also showed no significant benefit (OR = 0.32, 95%CI (0.07–1.32), p = 0.11, and OR = 1.67, 95%CI (0.59–4.67), p = 0.32, respectively). However, a single dose of multiple-donor FMT administered via colonoscopy (lower gastrointestinal (GI) administration) significantly improved patient symptoms compared with autologous FMT placebo (OR = 2.54, 95%CI (1.20–5.37), p = 0.01, and OR = 2.2, 95%CI (1.20–4.03), p = 0.01, respectively). The studies included in the analysis showed a low risk of bias and no publication bias. In conclusion, lower GI administration of a single dose of multiple-donor FMT significantly alleviates patient complaints compared with the autologous FMT used as a placebo. The underlying mechanisms need to be better understood, and further experimental studies are desired to fill the current gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeGastrointestinal MicrobiomeHumansFecal Microbiota TransplantationRandomized Controlled Trials as TopicTreatment OutcomeFeces

Stichwörter der Autor:innen

fecal microbiota transplantationgastrointestinal microbiomeirritable bowel syndromemeta-analysisrandomized controlled trial

Autor:innen und Institutionen

  • Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.
  • School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.
  • Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.
  • Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran.
  • NVH Global Health Academy, Nuvance Health, Danbury, CT 06810, USA.
  • St George and Sutherland Clinical School, UNSW Medicine, Sydney, NSW 2217, Australia.

ORCID-Profile: Parnian Jamshidi, Zahra Nariman, Benyamin Mohammadzadeh, Mohammad Javad Nasiri, Leonardo A Sechi

Zitieren

APA

Jamshidi, P., Farsi, Y., Nariman, Z., Hatamnejad, M. R., Mohammadzadeh, B., Akbarialiabad, H., Nasiri, M. J., & Sechi, L. A. (2023). Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Molecular Sciences, 24(19), 14562. https://doi.org/10.3390/ijms241914562

Vancouver

Jamshidi P, Farsi Y, Nariman Z, Hatamnejad MR, Mohammadzadeh B, Akbarialiabad H, et al. Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Molecular Sciences. 2023;24(19):14562. doi:10.3390/ijms241914562

BibTeX
@article{Jamshidi2023,
  author = {Jamshidi, Parnian and Farsi, Yeganeh and Nariman, Zahra and Hatamnejad, Mohammad Reza and Mohammadzadeh, Benyamin and Akbarialiabad, Hossein and Nasiri, Mohammad Javad and Sechi, Leonardo A},
  title = {Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {19},
  pages = {14562},
  doi = {10.3390/ijms241914562}
}
Kostenlos starten →